HBIO Strangle Strategy
HBIO (Harvard Bioscience, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through websites and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic laboratories. It primarily sells its products under the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS, Warner, DSI, Panlab, Hugo Sachs, and Buxco brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
HBIO (Harvard Bioscience, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $27.2M, a beta of 1.51 versus the broader market, a 52-week range of 3.8-9.4, average daily share volume of 42K, a public-listing history dating back to 2001, approximately 331 full-time employees. These structural characteristics shape how HBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.51 indicates HBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on HBIO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current HBIO snapshot
As of June 30, 2026, spot at $6.00, ATM IV 120.80%, IV rank 21.38%, expected move 34.63%. The strangle on HBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 52-day expiry.
Why this strangle structure on HBIO specifically: HBIO IV at 120.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a HBIO strangle, with a market-implied 1-standard-deviation move of approximately 34.63% (roughly $2.08 on the underlying). The 52-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HBIO should anchor to the underlying notional of $6.00 per share and to the trader's directional view on HBIO stock.
HBIO strangle setup
The HBIO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HBIO near $6.00, the first option leg uses a $6.30 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HBIO chain at a 52-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $6.30 | N/A |
| Buy 1 | Put | $5.70 | N/A |
HBIO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
HBIO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on HBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on HBIO
Strangles on HBIO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HBIO chain.
HBIO thesis for this strangle
The market-implied 1-standard-deviation range for HBIO extends from approximately $3.92 on the downside to $8.08 on the upside. A HBIO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current HBIO IV rank near 21.38% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HBIO at 120.80%. As a Healthcare name, HBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HBIO-specific events.
HBIO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HBIO alongside the broader basket even when HBIO-specific fundamentals are unchanged. Always rebuild the position from current HBIO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on HBIO?
- A strangle on HBIO is the strangle strategy applied to HBIO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With HBIO stock trading near $6.00, the strikes shown on this page are snapped to the nearest listed HBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HBIO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the HBIO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 120.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HBIO strangle?
- The breakeven for the HBIO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HBIO market-implied 1-standard-deviation expected move is approximately 34.63%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on HBIO?
- Strangles on HBIO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HBIO chain.
- How does current HBIO implied volatility affect this strangle?
- HBIO ATM IV is at 120.80% with IV rank near 21.38%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.